These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1913 related items for PubMed ID: 23486701

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B.
    Boglione L, Cariti G, Di Perri G, D'Avolio A.
    J Med Virol; 2016 Nov; 88(11):1953-9. PubMed ID: 27017932
    [Abstract] [Full Text] [Related]

  • 6. Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs.
    Ouzan D, Pénaranda G, Joly H, Khiri H, Pironti A, Halfon P.
    J Clin Virol; 2013 Dec; 58(4):713-7. PubMed ID: 24183313
    [Abstract] [Full Text] [Related]

  • 7. Pegylated interferon results in higher serological, but not virological, response rates when compared to continuous entecavir.
    Sonneveld MJ, Zoutendijk R, Hansen BE, Janssen HL.
    Antivir Ther; 2012 Dec; 17(8):1605-8. PubMed ID: 22898565
    [Abstract] [Full Text] [Related]

  • 8. Upregulation of NKG2C+ natural killer cells, TLR-2 expression on monocytes and downregulation of regulatory T-cells influence PEG-IFN treatment efficacy in entecavir-suppressed patients with CHB.
    Yan W, Wu D, Wang X, Chen T, Lai Q, Zheng Q, Jiang J, Hou J, Han M, Ning Q.
    Antivir Ther; 2015 Dec; 20(6):591-602. PubMed ID: 25814467
    [Abstract] [Full Text] [Related]

  • 9. Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients?
    Vlachogiannakos J, Papatheodoridis GV.
    Liver Int; 2015 Jan; 35 Suppl 1():100-6. PubMed ID: 25529094
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
    Lok AS, Trinh H, Carosi G, Akarca US, Gadano A, Habersetzer F, Sievert W, Wong D, Lovegren M, Cohen D, Llamoso C.
    Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350
    [Abstract] [Full Text] [Related]

  • 11. Treatment of pegylated interferon-α2a in chronic hepatitis B patients demonstrating a spontaneous decline in HBV DNA after acute exacerbation.
    Cai Q, Chen F, Shao X, Zhang X, Zhao Z, Gao Z.
    Antivir Ther; 2015 Sep; 20(2):217-24. PubMed ID: 25138110
    [Abstract] [Full Text] [Related]

  • 12. Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial.
    de Niet A, Jansen L, Stelma F, Willemse SB, Kuiken SD, Weijer S, van Nieuwkerk CMJ, Zaaijer HL, Molenkamp R, Takkenberg RB, Koot M, Verheij J, Beuers U, Reesink HW.
    Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):576-584. PubMed ID: 28522204
    [Abstract] [Full Text] [Related]

  • 13. Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B.
    Dakin H, Bentley A, Dusheiko G.
    Value Health; 2010 Dec; 13(8):922-33. PubMed ID: 20825619
    [Abstract] [Full Text] [Related]

  • 14. Hepatitis B Virus Pregenomic RNA Is Present in Virions in Plasma and Is Associated With a Response to Pegylated Interferon Alfa-2a and Nucleos(t)ide Analogues.
    Jansen L, Kootstra NA, van Dort KA, Takkenberg RB, Reesink HW, Zaaijer HL.
    J Infect Dis; 2016 Jan 15; 213(2):224-32. PubMed ID: 26216905
    [Abstract] [Full Text] [Related]

  • 15. Addition of nucleoside analogues to peg-IFNα-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFNα-2a: a randomized controlled trial.
    Xu Y, Wang X, Liu Z, Zhou C, Qi W, Jiao J, Yu F, Guo H, Zhao P, Wang J.
    BMC Gastroenterol; 2017 Aug 30; 17(1):102. PubMed ID: 28854883
    [Abstract] [Full Text] [Related]

  • 16. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML, Peng CY, Dai CY, Lai HC, Huang CF, Hsieh MY, Huang JF, Chen SC, Lin ZY, Yu ML, Chuang WL.
    PLoS One; 2015 Aug 30; 10(4):e0122259. PubMed ID: 25835020
    [Abstract] [Full Text] [Related]

  • 17. Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir.
    Takkenberg RB, Jansen L, de Niet A, Zaaijer HL, Weegink CJ, Terpstra V, Dijkgraaf MG, Molenkamp R, Jansen PL, Koot M, Rijckborst V, Janssen HL, Beld MG, Reesink HW.
    Antivir Ther; 2013 Aug 30; 18(7):895-904. PubMed ID: 23639931
    [Abstract] [Full Text] [Related]

  • 18. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.
    Piccolo P, Lenci I, Demelia L, Bandiera F, Piras MR, Antonucci G, Nosotti L, Mari T, De Santis A, Ponti ML, Sorbello O, Iacomi F, Angelico M.
    Antivir Ther; 2009 Aug 30; 14(8):1165-74. PubMed ID: 20032546
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of tenofovir and entecavir in patients who relapsed after pegylated interferon therapy.
    Köse Ş, Tatli Kiş T, Atalay S.
    J Chemother; 2019 Jul 30; 31(4):209-213. PubMed ID: 30963812
    [Abstract] [Full Text] [Related]

  • 20. Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon?
    Lampertico P, Viganò M, Colombo M.
    Liver Int; 2013 Feb 30; 33 Suppl 1():157-63. PubMed ID: 23286860
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 96.